Volume 75, Issue 9, Pages (May 2009)

Slides:

Advertisements

Similar presentations

Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long- term Nitric Oxide Synthase Inhibition by.

Advertisements

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Acute interstitial nephritis

Volume 70, Issue 10, Pages (November 2006)

Volume 82, Issue 6, Pages (September 2012)

Volume 72, Issue 11, Pages (December 2007)

Volume 82, Issue 1, Pages 7-8 (July 2012)

Acute interstitial nephritis

Volume 72, Issue 11, Pages (December 2007)

Volume 64, Issue 1, Pages (July 2003)

Functional evidence confirmed by histological localization: overlapping expression of erythropoietin and HIF-2α in interstitial fibroblasts of the renal.

Volume 83, Issue 5, Pages (May 2013)

Volume 58, Issue 6, Pages (December 2000)

Volume 62, Issue 1, Pages (July 2002)

Volume 66, Issue 5, Pages (November 2004)

Volume 60, Issue 3, Pages (September 2001)

JAK/STAT signaling in renal diseases

Paricalcitol attenuates cyclosporine-induced kidney injury in rats

Volume 85, Issue 3, Pages (March 2014)

Volume 59, Issue 5, Pages (May 2001)

Heterozygous disruption of activin receptor–like kinase 1 is associated with increased renal fibrosis in a mouse model of obstructive nephropathy José.

Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada

Volume 63, Issue 5, Pages (May 2003)

Volume 82, Issue 8, Pages (October 2012)

Volume 64, Pages S39-S45 (October 2003)

Volume 76, Issue 3, Pages (August 2009)

Volume 57, Issue 5, Pages (May 2000)

Volume 63, Issue 2, Pages (February 2003)

Volume 62, Issue 2, Pages (August 2002)

Volume 82, Issue 8, Pages (October 2012)

Volume 72, Issue 8, Pages (October 2007)

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Volume 79, Issue 4, Pages (February 2011)

Volume 70, Issue 10, Pages (November 2006)

Volume 61, Issue 1, Pages (January 2002)

Volume 74, Issue 10, Pages (November 2008)

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Volume 64, Issue 3, Pages (September 2003)

Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney Yee-Yung Ng, Chun-Cheng Hou, Wansheng.

Volume 64, Issue 2, Pages (August 2003)

Volume 72, Issue 12, Pages (December 2007)

Volume 63, Issue 2, Pages (February 2003)

Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity Fuad S. Shihab, Hong Yi, William M. Bennett, Takeshi.

Volume 67, Issue 2, Pages (February 2005)

C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis Gopala K. Rangan, Jeffrey W. Pippin, William.

Volume 75, Issue 6, Pages (March 2009)

Volume 73, Issue 6, Pages (March 2008)

20-HETE in acute kidney injury

Volume 73, Issue 7, Pages (April 2008)

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo

Urinary biomarkers: the future looks promising

Volume 59, Issue 5, Pages (May 2001)

M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang

Volume 65, Issue 6, Pages (June 2004)

Robert L. Chevalier, Barbara A. Thornhill, Alice Y. Chang

New drug toxicities in the onco-nephrology world

A man with a hole in his penis

Volume 58, Issue 3, Pages (September 2000)

The treatment of acute interstitial nephritis: More data at last

H. Raffi, J.M. Bates, Z. Laszik, S. Kumar Kidney International

Volume 58, Issue 4, Pages (October 2000)

Molecular mechanisms of renal hypertrophy: Role of p27Kip1

Volume 65, Issue 2, Pages (February 2004)

Volume 75, Issue 6, Pages (March 2009)

J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown

Volume 55, Issue 4, Pages (April 1999)

Volume 65, Issue 6, Pages (June 2004)

Eric N Haugen, Anthony J Croatt, Karl A. Nath Kidney International

Volume 65, Issue 1, Pages (January 2004)

Volume 75, Issue 2, Pages (January 2009)

Presentation transcript:

Volume 75, Issue 9, Pages 936-944 (May 2009) Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt William B. Lea, Eun Soo Kwak, James M. Luther, Susan M. Fowler, Zuofei Wang, Ji Ma, Agnes B. Fogo, Nancy J. Brown Kidney International Volume 75, Issue 9, Pages 936-944 (May 2009) DOI: 10.1038/ki.2009.9 Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 1 Effect of treatment on kidney injury. Effect of treatment on (a) kidney weight, (b) glomerular sclerosis, (c) tubulointerstitial fibrosis, and (d) renal vascular modeling. For post hoc comparisons, *P<0.01 versus sham, †P<0.05 versus uninephrectomy (Neph), ‡P<0.05 versus uninephrectomy+spironolactone (SPL), §P<0.05 versus uninephrectomy+FAD286, ∣∣P<0.05 versus uninephrectomy+Ang II+spironolactone, ¶P<0.05 versus uninephrectomy+Ang II+FAD286. Masson's trichrome (original magnification × 100) of the kidney in (e) control, (f) Ang II/salt-treated, (g) Ang II/salt+spironolactone-treated, and (h) Ang II/salt+FAD286-treated. The asterisks in (f) denote areas of tubulointerstitial fibrosis. Kidney International 2009 75, 936-944DOI: (10.1038/ki.2009.9) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 2 Effect of treatment on cardiac injury. Effect of treatment on (a) heart weight, (b) cardiac interstitial fibrosis, and (c) perivascular adventitial fibrosis. For post hoc comparisons, *P<0.01 versus sham, †P<0.05 versus uninephrectomy (Neph), ‡P<0.05 versus uninephrectomy+spironolactone (SPL), §P<0.05 versus uninephrectomy+FAD286, ∣∣P<0.05 versus uninephrectomy+Ang II+spironolactone, ¶P<0.05 versus uninephrectomy+Ang II+FAD286. (d) Focal area of subendocardial interstitial and perivascular fibrosis in heart from Ang II-treated rat (Masson's trichrome, original magnification × 100). Persistent perivascular fibrosis in Ang II/salt-treated rats receiving (e) spironolactone (× 400) and (f) FAD286. The asterisks in (d) denote cardiac interstitial fibrosis; arrowhead denotes perivascular/periadventitial fibrosis. Kidney International 2009 75, 936-944DOI: (10.1038/ki.2009.9) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 3 Effect of treatment on expression of PAI-1, osteopontin, and tumor growth factor β (TGF-β) mRNA in the kidney, heart, and aorta. For post hoc comparisons, *P<0.05 versus sham, †P<0.01 versus uninephrectomy (Neph), ‡P<0.01 versus uninephrectomy+spironolactone (SPL), §P<0.01 versus uninephrectomy+FAD286, ∣∣P<0.01 versus uninephrectomy+Ang II+spironolactone, ¶P<0.01 versus uninephrectomy+Ang II+FAD286, #P<0.01 versus uninephrectomy+Ang II. Kidney International 2009 75, 936-944DOI: (10.1038/ki.2009.9) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 4 Effect of spironolactone (SPL, 1 μm) on PAI-1 expression in rat vascular smooth muscle cells treated with angiotensin II (Ang II, 1 μm), aldosterone (aldo, 1 μm) or the combination. *P<0.05 versus vehicle, †P<0.05 versus Ang II alone, ‡P<0.05 versus spironolactone, §P<0.05 versus aldo+Ang II. Kidney International 2009 75, 936-944DOI: (10.1038/ki.2009.9) Copyright © 2009 International Society of Nephrology Terms and Conditions